Revelar Biotherapeutics launches for development of COVID-19 and other antibody therapeutics
pharmafile | November 16, 2021 | News story | Manufacturing and Production |
Twist Bioscience Corporation announced that it has launched Revelar Biotherapeutics, an independently operated, new biotechnology company to develop and commercialise an antibody, which neutralises all known variants of concern of the SARS-CoV-2 virus in preclinical studies.
Revelar Biotherapeutics is focused on developing and commercialising breakthrough therapeutic antibody products, to address critical unmet patient needs for COVID-19 and other therapeutic areas. The company will also leverage the antibody discovery and optimisation platform of Twist Biopharma, to license additional antibodies for up to five targets over the next four years.
Emily M Leproust, PhD, CEO and co-founder of Twist Bioscience commented: “In launching Revelar Biotherapeutics, we assembled an experienced executive leadership team with a proven track record of successful clinical and corporate development together with access to a series of antibody therapeutic leads.
“This transaction allows Twist to participate in the rapid advancement of therapeutic antibodies while remaining focused on our current opportunities in our core business as well as our biopharma and DNA data storage verticals. We look forward to having our first Twist Biopharma-discovered antibody enter clinical studies in 2022, pending the necessary requirements.”
David Scheer, chairman of the board of Revelar Biotherapeutics, added: “In parallel with the development of the antibody to treat SARS-CoV-2, which we believe has the potential to be delivered subcutaneously, we intend to build a pipeline of novel therapeutics by leveraging the robust Twist Biopharma antibody discovery and optimisation platform.
“Pairing Twist’s ability to identify single domain and multifunctional antibodies combined with the broad development expertise of the Revelar team sets the stage to move the needle in treating unmet medical needs.”
Lina Adams
